Maravai Lifesciences Holdings ( (MRVI) ) has provided an update.
On February 25, 2025, Maravai LifeSciences announced the postponement of its fourth quarter and full year 2024 earnings release and conference call. The delay is due to the need for additional time to complete year-end financial processes, including assessing a potential non-cash impairment charge related to a previous acquisition and correcting a revenue recognition error. Despite these issues, Maravai expects its full-year 2024 revenue to remain within the previously announced guidance range.
More about Maravai Lifesciences Holdings
Maravai LifeSciences Holdings, Inc. is a prominent life sciences company that provides essential products for the development of drug therapies, diagnostics, and novel vaccines. The company supports research on human diseases and offers products and services in nucleic acid synthesis and biologics safety testing to leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
YTD Price Performance: -26.96%
Average Trading Volume: 2,012,428
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.01B
Find detailed analytics on MRVI stock on TipRanks’ Stock Analysis page.